Hexarelin, often referred to as Examorelin and Hexarelin Acetate is a potent, synthetic hexapeptide, which is known for enhancing growth hormone release. Hersarelin has similar benefits and functions to GHRP-6. However, studies have shown that it is much more potent than GHRP-6 and can further increase growth hormone levels. During clinical trials, it revealed its ability to increase body strength, reduce body fat boost muscle growth. And in veterinary research, hexarelin is used for cardiovascular health.
Chemical Properties Pale Yellow Solid
Uses
Hexarelin peptide is a synthetic growth hormone-releasing peptide (GHRP).
hexarelin benefits Its benefits include:
Increase in lean muscle growth
Improved sleep quality
Enhance of athletic performance
Increased flexibility and joint health
Accelerated fat
loss Increased tendon and ligament strength
Enhanced recovery time
Side effects The side effects of Hexarelin include joint pain, water retention, increased cortisol levels, and desensitization of receptors.
Description
Examorelin (INN) (developmental code names EP-23905, MF-6003), also known as hexarelin, is a potent, synthetic, peptidic, orally-active, centrally-penetrant, and highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and a growth hormone secretagogue which was developed by Mediolanum Farmaceutici. It is a hexapeptide with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 which was derived from GHRP-6. These GH-releasing peptides have no sequence similarity to ghrelin, but mimic ghrelin by acting as agonists at the ghrelin receptor.
Examorelin substantially and dose-dependently increases plasma levels of growth hormone (GH) in animals and humans. In addition, similarly to pralmorelin (GHRP-2) and GHRP-6, it slightly and dose-dependently stimulates the release of prolactin, adrenocorticotropic hormone (ACTH), and cortisol in humans.[2][8] There are conflicting reports on the ability of examorelin to elevate insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 1 (IGFBP-1) levels in humans, with some studies finding no increase and others finding a slight yet statistically significant increase. Examorelin does not affect plasma levels of glucose, luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH) in humans.
Physiological
Examorelin releases more GH than does growth hormone-releasing hormone (GHRH) in humans, and produces synergistic effects on GH release in combination with GHRH, resulting in “massive” increases in plasma GH levels even with only low doses of examorelin. Pre-administration of GH blunts the GH-releasing effect of examorelin, while, in contrast, fully abolishing the effect of GHRH. Pre-treatment with IGF-1 also blunts the GH-elevating effect of examorelin. Testosterone, testosterone enanthate, and ethinylestradiol, though not oxandrolone, have been found to significantly potentiate the GH-releasing effects of examorelin in humans. In accordance, likely due to increases in sex steroid levels, puberty has also been found to significantly augment the GH-elevating actions of examorelin in humans.
A partial and reversible tolerance to the GH-releasing effects of examorelin occurs in humans with long-term administration (50–75% decrease in efficacy over the course of weeks to months).
Hexarelin online Chemical Properties
Boiling point 1403.6±65.0 °C(Predicted)
density 1.322±0.06 g/cm3(Predicted)
storage temp. -20°C
solubility H2O: soluble1mg/mL, clear, colorless
pka 13.42±0.46(Predicted)
form A crystalline solid
InChIKey RVWNMGKSNGWLOL-GIIHNPQRSA-N
SMILES C(N)(=O)[C@H](CCCCN)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1C2=C(C=CC=C2)NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC1C2=C(C=CC=C2)NC=1C)NC(=O)[C@H](CC1N=CNC=1)N
CAS DataBase Reference 140703-51-1(CAS DataBase Reference)
More Introduction:https://en.wikipedia.org/wiki/Examorelin
